One in Five Older Women With Early Breast Cancer Experience ... HealthNewsDigest.com, NY - 29 minutes ago "Timeliness of post-surgical radiotherapy is important in reducing the risk of subsequent recurrence or new breast malignancies in patients with early ...
Breast cancer: What you need to know Food Consumer, IL - Both the shortened menstrual circle and lowered estradiol may indicate lower risk for hormone-sensitive breast cancer. Seaweed may reduce breast cancer risk...
Low radiation exposure tied to cancer risk The Daily Yomiuri, Japan - Aug 4, 2008 However, the women's risk of suffering uterine cancer and breast cancer were 1.76 times and 1.24 to 1.47 times higher, respectively. ...
Craig W. Philips Takes Helm at CTI FOXBusiness - Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. ...CTIC - OTC:CMTX
Genomic Health Announces Second Quarter 2008 Financial Results and ... eMediaWorld.com Newswire Press Release Distribution Service (press release), AZ - 44 minutes ago Product revenue from the Oncotype DX(R) breast cancer assay was $26.3 million in the second quarter of 2008, an increase of 81 percent compared to $14.6 ...GHDX
Migration Patterns and Breast Cancer Risk in Asian-American Women - RG Ziegler, RN Hoover, MC Pike, A Hildesheim, AMY … - jnci, 1993 - jnci.oxfordjournals.org ... Migration Patterns and BreastCancerRisk in Asian-American Women. ... Results: A sixfold
gradient in breastcancerrisk by migration patterns was observed. ...
Risk factors for breast cancer in women with proliferative breast disease. - WD Dupont, DL Page - N Engl J Med, 1985 - ncbi.nlm.nih.gov ... Although cysts alone did not substantially elevate the risk, women with both cysts
and a family history of breastcancer had a risk 2.7 times higher than that ...
The effect of raloxifene on risk of breast cancer in postmenopausal women - SR Cummings, S Eckert, KA Krueger, D Grady, TJ … - feedback, 2005 - biomedcentral.com ... Paper Report. The effect of raloxifene on risk of breastcancer in postmenopausal
women SR Cummings, S Eckert, KA Krueger, D Grady, TJ Powles, JA Cauley, L ...
Dual effects of weight and weight gain on breast cancer risk - Z Huang, SE Hankinson, GA Colditz, MJ Stampfer, DJ … - JAMA, 1997 - Am Med Assoc ... Dual effects of weight and weight gain on breastcancerrisk. ... Social and Dietary
Changes Associated with Obesity and BreastCancerRisk Selvan et al. ...
Effects of Individualized Breast Cancer Risk Counseling: a Randomized Trial - C Lerman, E Lustbader, B Rimer, M Daly, S Miller, … - jnci, 1995 - jnci.oxfordjournals.org ... 87, No. 4, 286-292, February 15, 1995 ? 1995 Oxford University Press Effects of
Individualized BreastCancerRisk Counseling: a Randomized Trial. ...
Source: Google Scholar
Study: Estratest Doubles Breast Cancer Risk
CHICAGO (AP) -- Older women who take hormone pills that combine estrogen and testosterone more than double their risk of breast cancer, according to a study of more than 70,000 nurses.
"This type of hormone therapy may help with mood, libido and bone mineral density, but the possible risk of breast cancer may outweigh these benefits," said study co-author Rulla Tamimi of Harvard Medical School.
The findings, published in Monday's Archives of Internal Medicine, add to the evidence that certain types of hormone supplements, such as estrogen-progestin pills, increase women's risk of breast cancer, strokes and heart attacks. Earlier research also found a greater breast cancer risk in women with higher natural levels of testosterone.
The overall risk of breast cancer among the participants in the latest study was small, with 17 cases of the disease among the 500 or so women who took the estrogen-testosterone combination.
Women's natural levels of estrogen and testosterone decline with menopause.
Only about 2 percent of women taking hormones in the study in 2000 used a form that included testosterone. But usage climbed during the 24 years of the study as evidence appeared linking the hormone combination to better bone density, improved mood and greater sexual enjoyment.
Estrogen-testosterone pills are sold under the brand names Estratest and Estratest H.S. by Solvay Pharmaceuticals of Marietta, Ga. Those brand names appear on a Washington-based advocacy group's "Worst Pills" list because of breast cancer risk.
"We strongly urge women not to use this product or similar products from compounding pharmacists," said Dr. Sidney Wolfe, director of Public Citizen's Health Research Group, which produces the Worst Pills list.
The Food and Drug Administration has asked Solvay for evidence the drug eases hot flashes in menopausal women, as the label claims. The company has requested a hearing on the matter.
The drug was approved 30 years ago, before such evidence was required.
The new study used data from the long-running Nurses' Health Study. The women who took estrogen and testosterone after menopause had a 2 1/2 times higher risk of developing breast cancer than women who never took hormones. Most of the women taking the combination used Estratest.
"The company has not yet had the opportunity to review the details of the study or the content of the article," said Solvay spokesman Gabrielle Braswell.
The researchers took into account other breast cancer risk factors, such as family history, weight and age at menopause and still found an increased risk associated with estrogen-testosterone pills.
